Selected research
Industry Research
Leukocyte Surface Antigen CD47 Industry Research Report 2026
Market perspective
The global Leukocyte Surface Antigen CD47 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Leukocyte Surface Antigen CD47 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Leukocyte Surface Antigen CD47 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Leukocyte Surface Antigen CD47 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Leukocyte Surface Antigen CD47 include Trillium Therapeutics Inc, Surface Oncology Inc, Forty Seven Inc, Celgene Corp and Aurigene Discovery Technologies Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Leukocyte Surface Antigen CD47 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Leukocyte Surface Antigen CD47 Market by Company
Trillium Therapeutics Inc
Surface Oncology Inc
Forty Seven Inc
Celgene Corp
Aurigene Discovery Technologies Ltd
Leukocyte Surface Antigen CD47 Segment by Type
PSTx-23
CC-90002
B-6H12
ALX-148
Others
Leukocyte Surface Antigen CD47 Segment by Application
Ischemia Reperfusion Injury
Kindney Transplant Rejection
Ovarian Cancer
Lymphoma
Others
Leukocyte Surface Antigen CD47 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leukocyte Surface Antigen CD47 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leukocyte Surface Antigen CD47 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leukocyte Surface Antigen CD47.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Leukocyte Surface Antigen CD47 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Leukocyte Surface Antigen CD47 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Leukocyte Surface Antigen CD47 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PSTx-23
- CC-90002
- B-6H12
- ALX-148
- Others
Applications
- Ischemia Reperfusion Injury
- Kindney Transplant Rejection
- Ovarian Cancer
- Lymphoma
- Others
Companies covered
- Trillium Therapeutics Inc
- Surface Oncology Inc
- Forty Seven Inc
- Celgene Corp
- Aurigene Discovery Technologies Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Leukocyte Surface Antigen CD47 Market Size (2021-2032)
- 2.2.2 Global Leukocyte Surface Antigen CD47 Sales (2021-2032)
- 2.2.3 Global Leukocyte Surface Antigen CD47 Market Average Price (2021-2032)
- 2.3 Leukocyte Surface Antigen CD47 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 PSTx-23
- 2.3.3 CC-90002
- 2.3.4 B-6H12
- 2.3.5 ALX-148
- 2.3.6 Others
- 2.4 Leukocyte Surface Antigen CD47 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ischemia Reperfusion Injury
- 2.4.3 Kindney Transplant Rejection
- 2.4.4 Ovarian Cancer
- 2.4.5 Lymphoma
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Leukocyte Surface Antigen CD47 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Leukocyte Surface Antigen CD47 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Leukocyte Surface Antigen CD47 Revenue of Manufacturers (2021-2026)
- 3.4 Global Leukocyte Surface Antigen CD47 Average Price by Manufacturers (2021-2026)
- 3.5 Global Leukocyte Surface Antigen CD47 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Leukocyte Surface Antigen CD47, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Leukocyte Surface Antigen CD47, Product Type & Application
- 3.8 Global Manufacturers of Leukocyte Surface Antigen CD47, Established Date
- 3.9 Global Leukocyte Surface Antigen CD47 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Trillium Therapeutics Inc
- 4.1.1 Trillium Therapeutics Inc Company Information
- 4.1.2 Trillium Therapeutics Inc Business Overview
- 4.1.3 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Trillium Therapeutics Inc Leukocyte Surface Antigen CD47 Product Portfolio
- 4.1.5 Trillium Therapeutics Inc Recent Developments
- 4.2 Surface Oncology Inc
- 4.2.1 Surface Oncology Inc Company Information
- 4.2.2 Surface Oncology Inc Business Overview
- 4.2.3 Surface Oncology Inc Leukocyte Surface Antigen CD47 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Surface Oncology Inc Leukocyte Surface Antigen CD47 Product Portfolio
- 4.2.5 Surface Oncology Inc Recent Developments
- 4.3 Forty Seven Inc
- 4.3.1 Forty Seven Inc Company Information
- 4.3.2 Forty Seven Inc Business Overview
- 4.3.3 Forty Seven Inc Leukocyte Surface Antigen CD47 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Forty Seven Inc Leukocyte Surface Antigen CD47 Product Portfolio
- 4.3.5 Forty Seven Inc Recent Developments
- 4.4 Celgene Corp
- 4.4.1 Celgene Corp Company Information
- 4.4.2 Celgene Corp Business Overview
- 4.4.3 Celgene Corp Leukocyte Surface Antigen CD47 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Celgene Corp Leukocyte Surface Antigen CD47 Product Portfolio
- 4.4.5 Celgene Corp Recent Developments
- 4.5 Aurigene Discovery Technologies Ltd
- 4.5.1 Aurigene Discovery Technologies Ltd Company Information
- 4.5.2 Aurigene Discovery Technologies Ltd Business Overview
- 4.5.3 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Aurigene Discovery Technologies Ltd Leukocyte Surface Antigen CD47 Product Portfolio
- 4.5.5 Aurigene Discovery Technologies Ltd Recent Developments
5 Global Leukocyte Surface Antigen CD47 Market Scenario by Region
- 5.1 Global Leukocyte Surface Antigen CD47 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Leukocyte Surface Antigen CD47 Sales by Region: 2021-2032
- 5.2.1 Global Leukocyte Surface Antigen CD47 Sales by Region: 2021-2026
- 5.2.2 Global Leukocyte Surface Antigen CD47 Sales by Region: 2027-2032
- 5.3 Global Leukocyte Surface Antigen CD47 Revenue by Region: 2021-2032
- 5.3.1 Global Leukocyte Surface Antigen CD47 Revenue by Region: 2021-2026
- 5.3.2 Global Leukocyte Surface Antigen CD47 Revenue by Region: 2027-2032
- 5.4 North America Leukocyte Surface Antigen CD47 Market Facts & Figures by Country
- 5.4.1 North America Leukocyte Surface Antigen CD47 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
- 5.4.3 North America Leukocyte Surface Antigen CD47 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Leukocyte Surface Antigen CD47 Market Facts & Figures by Country
- 5.5.1 Europe Leukocyte Surface Antigen CD47 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
- 5.5.3 Europe Leukocyte Surface Antigen CD47 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Leukocyte Surface Antigen CD47 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Leukocyte Surface Antigen CD47 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Leukocyte Surface Antigen CD47 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Leukocyte Surface Antigen CD47 Market Facts & Figures by Country
- 5.7.1 South America Leukocyte Surface Antigen CD47 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
- 5.7.3 South America Leukocyte Surface Antigen CD47 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Leukocyte Surface Antigen CD47 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Leukocyte Surface Antigen CD47 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Leukocyte Surface Antigen CD47 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Leukocyte Surface Antigen CD47 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Leukocyte Surface Antigen CD47 Sales by Type (2021-2032)
- 6.1.1 Global Leukocyte Surface Antigen CD47 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Leukocyte Surface Antigen CD47 Sales Market Share by Type (2021-2032)
- 6.2 Global Leukocyte Surface Antigen CD47 Revenue by Type (2021-2032)
- 6.2.1 Global Leukocyte Surface Antigen CD47 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Leukocyte Surface Antigen CD47 Revenue Market Share by Type (2021-2032)
- 6.3 Global Leukocyte Surface Antigen CD47 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Leukocyte Surface Antigen CD47 Sales by Application (2021-2032)
- 7.1.1 Global Leukocyte Surface Antigen CD47 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Leukocyte Surface Antigen CD47 Sales Market Share by Application (2021-2032)
- 7.2 Global Leukocyte Surface Antigen CD47 Revenue by Application (2021-2032)
- 7.2.1 Global Leukocyte Surface Antigen CD47 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Leukocyte Surface Antigen CD47 Revenue Market Share by Application (2021-2032)
- 7.3 Global Leukocyte Surface Antigen CD47 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Leukocyte Surface Antigen CD47 Value Chain Analysis
- 8.1.1 Leukocyte Surface Antigen CD47 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Leukocyte Surface Antigen CD47 Production Mode & Process
- 8.2 Leukocyte Surface Antigen CD47 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Leukocyte Surface Antigen CD47 Distributors
- 8.2.3 Leukocyte Surface Antigen CD47 Customers
9 Global Leukocyte Surface Antigen CD47 Analyzing Market Dynamics
- 9.1 Leukocyte Surface Antigen CD47 Industry Trends
- 9.2 Leukocyte Surface Antigen CD47 Industry Drivers
- 9.3 Leukocyte Surface Antigen CD47 Industry Opportunities and Challenges
- 9.4 Leukocyte Surface Antigen CD47 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst